CXBS (Corix Bioscience) FCF Margin %: 0.00% (As of Sep. 2017)


What is Corix Bioscience FCF Margin %?

Corix Bioscience CXBS -99.00% FCF Margin % is 0.00% as of Sep. 2017.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Corix Bioscience's Free Cash Flow for the three months ended in Sep. 2017 was $-1.72 Mil. Corix Bioscience's Revenue for the three months ended in Sep. 2017 was $0.00 Mil. Therefore, Corix Bioscience's FCF Margin % for the quarter that ended in Sep. 2017 was 0.00%.

As of today, Corix Bioscience's current FCF Yield % is 0.00%.

The historical rank and industry rank for Corix Bioscience's FCF Margin % or its related term are showing as below:

CXBS' s FCF Margin % Range Over the Past 10 Years
Min: -451.3   Med: 0   Max: 0
Current: -451.3

CXBS's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.51 vs CXBS: -451.30

Corix Bioscience FCF Margin % Related Terms

Corix Bioscience FCF Margin % Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience FCF Margin % Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -270.46

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CXBS vs BKIT, YBAO, HSTI: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corix Bioscience FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's FCF Margin % falls into.


Corix Bioscience FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Corix Bioscience's FCF Margin for the fiscal year that ended in Dec. 2016 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2016 )/Revenue (A: Dec. 2016 )
=-1.877/0.694
=-270.46 %

Corix Bioscience's FCF Margin for the quarter that ended in Sep. 2017 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2017 )/Revenue (Q: Sep. 2017 )
=-1.722/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Corix Bioscience (CXBS) has a FCF Margin % of 0.00% as of Sep. 2017. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's FCF Margin % too high?
Corix Bioscience's current FCF Margin % is 0.00%.
How does Corix Bioscience's FCF Margin % compare to BKIT and YBAO?
Corix Bioscience's FCF Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Corix Bioscience and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corix Bioscience's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current FCF Margin % is 0.00% as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.